Investors tracking new listings continue to show strong interest in the primary market while also following broader topics like Exide Share Price and SME IPO Means. One of the latest IPOs to open is the Corona Remedies public issue. With steady attention on the pharmaceutical sector, the IPO has generated early traction. Here is a complete breakdown of the GMP trend, subscription status, IPO specifications and what investors should watch as the issue progresses.
About Corona Remedies
Corona Remedies is a pharmaceutical company operating across multiple therapeutic categories such as women’s health, gastro, pain management, cardiology and dermatology. The company has expanded rapidly due to its diverse product portfolio and strong distribution network. The IPO aims to provide liquidity to existing shareholders through an Offer for Sale.
Corona Remedies IPO Details
Here are the key IPO specifications investors need to know:
• IPO opening date: 8 December
• IPO closing date: 10 December
• Issue size: Around ₹655 crore (entirely an Offer for Sale)
• Price band: ₹1,008 to ₹1,062 per share
• Lot size for retail investors: 14 shares
• Minimum investment: Approximately ₹14,868 at the upper price band
• Face value: ₹10 per share
• Allotment date: 11 December
• Listing date: Expected on 15 December on NSE and BSE
Since the IPO is entirely an OFS, the company will not receive new capital. Instead, existing shareholders will sell part of their stake.
Day 1 Subscription Status
On Day 1 of the IPO, subscription activity was steady. Retail investor participation was comparatively stronger, with the retail portion seeing healthy bids. Non institutional investors also showed moderate activity in the early hours, while institutional investor participation tends to increase toward the last day.
Pharmaceutical companies generally attract attention due to consistent demand, stable cash flows and defensive sector positioning. This helped push early subscription numbers.
Grey Market Premium (GMP) Trend
The grey market premium on the first day indicated positive sentiment. The GMP suggested expectations of a premium on listing, although GMP is unofficial and fluctuates frequently. A steady GMP usually indicates confidence in the company’s fundamentals and demand in the unlisted market.
Important Things For Investors To Evaluate
Before applying, investors should carefully review:
• Revenue growth and margin performance
• Strength of therapeutic product portfolio
• Dependence on any single product segment
• Competitive landscape in branded formulations
• Regulatory and compliance track record
Since the company is not raising fresh capital, its growth plans will depend on internal cash flows and operational performance.
Conclusion
The Corona Remedies IPO opened with encouraging interest from retail investors, supported by steady GMP trends and the pharmaceutical sector’s defensive nature. Many investors who explore Exide Share Price and SME IPO Means continue to follow pharma IPOs closely, as the sector benefits from consistent demand and broad healthcare requirements in India. As the subscription window progresses, further updates on investor categories will help shape expectations for listing performance. At the same time, reviewing the company’s financial stability, product portfolio and plans for market expansion will be important for those evaluating participation. With long term healthcare spending in India expected to grow steadily, the IPO offers an opportunity to invest in a business linked to essential consumer needs, while considering both potential and valuation risks before making a final decision.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis – Research & Ranking. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.
